SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

ABEO

Abeona Therapeutics Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS miss and widening net loss are concerning, but the 31% QoQ revenue growth and CMS NTAP catalyst provide a counterbalance. Monitor Q3 2026 for continued patient treatment momentum and cash burn rate; the NTAP designation in October could drive hospital adoption and revenue acceleration.

DirectionMixed
Confidencehigh
Horizonweeks

ZEVASKYN

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially launched in the U.S. (April 2025).
Next catalyst
None dated

What to watchZEVASKYN is already approved and generating revenue, so the binary approval catalyst is behind it. Watch quarterly commercial metrics (patient starts, revenue growth, treatment center expansion) and the CMS NTAP designation effective October 2026 for reimbursement tailwinds. The stock's ~214% implied upside to the mean analyst target reflects optimism on commercial ramp, but ongoing cash burn and EPS misses warrant caution.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$6.35
T+0 close · Aug 13, 2026 · via day close
Latest settled
−6.07%
T+5 · $5.96
Vs SPY
−4.10%
α at T+5
Next horizon
T+20
due 2mo ago
  1. T+0 · Aug 13 $6.35entry
  2. T+1 · 3mo ago −5.67%α −5.48% · $5.99
  3. T+5 · 3mo ago −6.07%α −4.10% · $5.96
  4. T+20 · due 2mo ago Pending
  5. T+60 · due 11d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 missed the consensus estimate of -$0.24 by 45.8%, and the net loss widened to -$20.2M from -$17.1M in Q1, driven by a $7.2M non-cash warrant liability charge. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst, but the EPS miss and ongoing cash burn temper the outlook.

Key Financial Metrics

EPS
−$0.35
est −$0.24 · -45.8%
Revenue
$11.4M
est $12.2M · -6.7%
Rating
miss

Key Facts

  • Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026.
  • Five patients treated with ZEVASKYN in Q2; revenue recognized for four due to one batch below threshold.
  • EPS of -$0.35 missed consensus estimate of -$0.24 by 45.8%.
  • Net loss widened to -$20.2M from -$17.1M in Q1, including a $7.2M non-cash warrant liability charge.
  • Cash, equivalents, and investments at $146.8M as of June 30, 2026, down from $191.4M at year-end 2025.
  • CMS NTAP designation for ZEVASKYN effective October 1, 2026, expected to support hospital adoption.
  • QTC network expanded to seven sites; Cincinnati Children's activated in Q3 2026.

Financial Impact

Q2 revenue $11.4M vs consensus $12.2M; EPS -$0.35 vs consensus -$0.24; net loss -$20.2M

revenueepsnet losscash

Risk Factors

  • EPS miss of 45.8% vs consensus signals operational underperformance relative to expectations.
  • Cash burn continues; cash declined $44.6M in H1 2026, raising potential dilution risk.
  • Revenue recognition risk: one of five Q2 treatments did not meet batch release specifications, highlighting manufacturing yield uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3344400

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026